1. Scrip
  2. >>New Products

Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress

No Update On Plans For MDD Resubmission

 
• By Mandy Jackson

Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.

Wooden blocks with launching rocket graphic arranged in pyramid shape and a man is holding the top one.
Sage has finished building its commercial team for the December launch • Source: Shutterstock

The US Food and Drug Administration approval of Zurzuvae (zuranolone) in August did not go according to plan for Sage Therapeutics, Inc. and partner Biogen, Inc. While it was cleared to treat postpartum depression (PPD), the companies received a complete response letter (CRL) indicating an additional clinical trial would be needed to support approval in major depressive disorder (MDD), but the drug’s launch for new mothers with PPD is now progressing as expected following Drug Enforcement Administration scheduling.

Key Takeaways

  • Sage said Zurzuvae will launch for PPD in December now that the DEA has scheduled the drug.

Sage said as part of its third quarter financial update on 7 November that Zurzuvae will officially reach the market...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

More from Scrip